Table 2 Baseline characteristics of study participants [n is variable depending on availability of data]
Variable | Frequency | Proportion (%) |
|---|---|---|
ART Usage (n = 461) |  |  |
ART-experienced ART-naïve | 431 30 | 93.5 6.5 |
WHO Clinical Staging (n = 453) |  |  |
1 2 3 | 382 64 7 | 84.3 14.1 1.5 |
VL (copies/ml) (n = 430) |  |  |
< 50 50 − 999 ≥ 1000 | 397 27 6 | 92.3 6.3 1.4 |
CD4 (cells/mm3)(n = 403) |  |  |
< 200 200 − 350 351 − 500 > 500 | 28 47 90 238 | 6.9 11.7 22.3 59.1 |
Previous ART Regimen (n = 431) |  |  |
Tenofovir/Emtricitabine/Efavirenz Other | 411 20 | 95.4 4.6 |